Clinical trialCLINICALTRIALSMay 6
Trial Now Recruiting: Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) (NCT07447648)
Researchers are looking for 52 patients with a rare genetic condition called homozygous familial hypercholesterolemia (HoFH) to join a study. HoFH causes dangerously high cholesterol levels from birth, which leads to heart disease at a young age. This study will test whether a new cholesterol-lowering drug called Evinacumab, combined with other treatments, can reduce the buildup of plaque in heart arteries.
WHY IT MATTERSIf you have HoFH, this trial offers access to Evinacumab—a newer cholesterol-lowering therapy—and detailed imaging to measure whether it's actually reducing the dangerous plaque buildup in your coronary arteries.